Background Pneumoconiosis is a chronic inflammatory disease that cannot be completely cured. Therefore, how to control lung inflammation and delay of the body aging is one of the keys to treating pneumoconiosis. The studies in past two decades suggested that many small molecule drugs are able to enhance cardiopulmonary function. Objective To explore the effects of homeopathic dosing and combined dosing of β-nicotinamide mononucleotide and taurine on experimental silicosis in rats. Methods Seventy-two SD specific pathogen-free rats were randomized into 4 groups (18 mice in each group): negative control group (ultrapure water, without dust), positive control group, homeopathic treatment group, co-administered treatment group. One mL of quartz dust suspension was injected into the rat trachea by disposable non-exposed tracheal injection method (50 mg·mL⁻¹) to establish a rat silicosis model. Rats were administered by gavage since the 4th day after dust exposure. The homeopathic treatment group rats received taurine solution (0.03 g·mL⁻¹) in the morning and β-nicotinamide mononucleotide (0.03 g·mL⁻¹) in the afternoon; the co-administered treatment group rats received a mixed solution (0.015 g·mL⁻¹ β-nicotinamide mononucleotide + 0.015 g·mL⁻¹ taurine) twice, in the morning and afternoon respectively. The positive and negative control groups received equivalent of ultrapure water in the morning and afternoon. All groups of rats were administered 5 d a week for a total of 6 weeks. The rats were neutralized after 6 weeks of administration. Organ coefficient, lung hydroxyproline content, whole lung dry and wet weights, whole lung free silica content, and cell count and classification in lung lavage fluid were measured and calculated, and lung histopathological changes in lung samples were observed. Results Compared with the positive control group, the whole lung wet weight, whole lung dry weight , total cell count, neutrophil rate, lung organ coefficient, lung hydroxyproline content, and whole lung free silica content were reduce in the homeopathic treatment group, and the co-administered treatment group (P＜0.05). Compared with the negative control group, the total cell count, neutrophil rate, lung organ coefficient, lung hydroxyproline content, and whole lung free silica content were elevated in the homeopathic treatment group and the co-administered treatment group, the whole lung dry weight was elevated in the co-administered treatment group, and those differences were all statistically significant (P＜0.05). The rat lung histopathological results showed that, in the positive control group, round or oval nodules were formed in the lung tissue, which were phagocytic cellular nodules, and the alveolar structures in some areas still existed. The histopathological changes in the homeopathic treatment group and the co-administered treatment group were similar to those of the positive group, but less severe. No pathological change was observed in the lung tissue of the negative control group. Conclusion Some improvement and dust removal in experimental silicosis rats by homeopathic dosing and combined dosing of β-nicotinamide mononucleotide and taurine are observed.

Autologous blood donation is an important strategy of blood conservation. The Administrative Measures for the Clinical Use of Blood in Medical Institutions (Order No. 85 of the National Health Commission) requires medical institutions to promote the implementation of autologous blood donation actively. The clinical practice guidelines for patient blood management also recommend the proactive use of autologous blood donation to reduce the reliance on allogeneic blood. Preoperative autologous blood donation (PABD) is one of the autologous blood donation with wide range of indications, easy to operate, and can effectively reduce the transfusion of allogeneic blood. However, the performance of PABD in China is unsatisfactory due to various factors such as the patient composition of medical institutions, the implementation of outpatient department of blood transfusion, the level of attention paid to this issue, and the fact that traditional PABD do not meet clinical requirements. Therefore, improving the PABD model and exploring new PABD technology, as well as promoting their clinical application, are critical measures to meet the development requirements of patient blood management and to alleviate the shortage of blood supply. This article summarizes the improvements in the PABD model, and a novel PABD technology of PABD—preoperative deep apheresis of autologous red blood cells and/or platelets (deep apheresis autologous blood storage technology), and the current situation of clinical application of PABD to provide paradigm for clinical transfusion.

In recent years， the incidence of pulmonary nodules has kept rising. To give full play to the advantages of traditional Chinese medicine （TCM） in the treatment of pulmonary nodules and identify the breakthrough points of integrating TCM with Western medicine， the China Association of Chinese Medicine organized medical experts in TCM and western medicine to carry out in-depth discussion regarding this disease. The discussion encompassed the modern medical advances， TCM theories of etiology and pathogenesis， the role and advantages of TCM in the whole course management of pulmonary nodules， contents and methods of research on pulmonary nodules， and science popularization work， aiming to provide a reference for clinical practice and scientific research. After discussion， the experts concluded that the occurrence of pulmonary nodules was rooted in the deficiency of the lung and spleen and triggered by phlegm dampness， blood stasis， and Qi stagnation. TCM can treat pulmonary nodules by controlling and reducing nodules， improving physical constitution， ameliorating multi-system nodular diseases， reducing anxiety and avoiding excessive diagnosis and treatment， and serving as an alternative for patients who are unwilling or unfit for surgical treatment. At present， the optimal diagnosis and treatment strategy for pulmonary nodules has not been formed， which needs to be further studied from multiple perspectives such as clinical epidemiology， biology， and evidence-based medicine. The primary task of current research is to find out the advantages， effective prescriptions， and target populations and determine the effective outcomes of TCM in the treatment of pulmonary nodules. At the same time， basic research should be carried out to explore the etiology and biological behaviors of pulmonary nodules. The expert consensus on the diagnosis and treatment of pulmonary nodules with integrated TCM and Western medicine needs to be continuously revised to guide clinicians to conduct standardized， scientific， and accurate effective diagnosis and treatment.

Objective:To investigate the characteristics of early motor development in small for gestational age (SGA) infants at high risk of brain injury.Methods:This study retrospectively enrolled a total of 81 SGA infants and appropriate for gestational age (AGA) infants who were at high risk of brain injury and attended outpatient follow-up visits in Xi'an Children's Hospital from February to October 2022. Seventeen SGA infants (SGA group) and 24 AGA infants (AGA group) were assessed for motor development using the Test of Infant Motor Performance (TIMP) at 2-5 weeks of corrected age (CA) and 20 SGA infants (SGA group) and 20 AGA infants (AGA group) were assessed at 14-17 weeks of CA. Independent samples t-test, rank-sum test, and Chi-square test were used to compare the demographic characteristics, high-risk factors of brain injury, and TIMP scores between the two groups. Results:At 2-5 weeks and 14-17 weeks of CA, the birth weights of SGA group were both less than those of AGA group [(1 817.1±440.3) vs. (2 630.0±560.9) g, t=－4.98; (1 752.0±434.4) vs. (2 226.3±699.8) g, t=－2.58; both P<0.05], but there were no significant differences in gestational age at birth or high-risk factors of brain injury between the two groups (all P>0.05). (1) At 2-5 weeks of CA: SGA group had lower total TIMP score [(71.6±13.7) vs. (80.5±11.5) scores, t=－2.26, P=0.029], elicited item score [61.0 scores (41.0-85.0 scores) vs. 69.1 scores (49.0-96.0 scores), Z=－2.15, P=0.037], sitting position score [8.8 scores (3.0-19.0 scores) vs. 11.2 scores (5.0-22.0 scores), Z=－2.07, P=0.038], and prone position score [(9.8±3.1) vs. (12.3±3.1) scores, t=－2.19, P=0.034] when compared with AGA group. (2) At 14-17 weeks of CA: The standing position score of the SGA group was lower than that of the AGA group [6.5 scores (4.0-11.0 scores) vs. 7.7 scores (2.0-11.0 scores), Z=－2.05, P=0.040], but no statistical difference was observed in the total TIMP score or the scores of sitting, supine, prone, turning, and lateral positions between the two groups (all P>0.05). Conclusion:Early motor performance of SGA infants is inferior to AGA infants before five months of age, which is embodied in the poor head control at 2-5 weeks of CA that further affects the stability of standing posture in them at 14-17 weeks of CA.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.

Attracting overseas medical consumption is the driving force behind the development of the medical industry in China's current"dual circulation"new development pattern.The progress of domestic medical technology and the improvement of service quality,the development of the economy and society,the enhancement of residents'health awareness,the increase of government investment in the health field,the advantages of the medical market and price competition,the guidance and support of government policies,international medical exchanges and cooperation,and the improvement of the medical insurance system are the main driving factors for attracting overseas medical consumption.Improving the level of medical technology,stimulating the vitality of attracting medical consumption,increasing the supply of medical consumption,unleashing the potential of attracting medical consumption,improving the quality of medical services,building support for attracting medical consumption to return,optimizing the medical consumption environment,creating an atmosphere for attracting medical consumption,and regulating overseas medical consumption,injecting the momentum of attracting medical consumption to return are the main implementation ways to attract overseas medical consumption to return.